Clinical data corroborate these findings, in which stage-II colorectal cancer patients who presented the overexpression of all three of these proteins in tumor samples had worse clinical outcomes compared with patients with elevated levels of only ACSL1, ACSL4, or SCD1 alone. Here, SCD is linked to colorectal cancer.